336 related articles for article (PubMed ID: 30955196)
21. Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer.
Wang Y; Song G; Wang Y; Qiu L; Qin X; Liu H; Li F; Wang X; Li F; Guo S; Zhang Y; Li Z
J Proteome Res; 2014 Feb; 13(2):710-9. PubMed ID: 24295561
[TBL] [Abstract][Full Text] [Related]
22. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
[TBL] [Abstract][Full Text] [Related]
23. Serum galectins as potential biomarkers of inflammatory bowel diseases.
Yu TB; Dodd S; Yu LG; Subramanian S
PLoS One; 2020; 15(1):e0227306. PubMed ID: 31929564
[TBL] [Abstract][Full Text] [Related]
24. CD8
Dai SX; Gu HX; Lin QY; Huang SZ; Xing TS; Zhang QF; Wu G; Chen MH; Tan WE; Jian HJ; Zheng ZW; Zhong T; Zhang MH; Cheng XF; Huang P; Liao GJ; Sha WH
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):693-702. PubMed ID: 28502591
[TBL] [Abstract][Full Text] [Related]
25. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.
Dawiskiba T; Deja S; Mulak A; Ząbek A; Jawień E; Pawełka D; Banasik M; Mastalerz-Migas A; Balcerzak W; Kaliszewski K; Skóra J; Barć P; Korta K; Pormańczuk K; Szyber P; Litarski A; Młynarz P
World J Gastroenterol; 2014 Jan; 20(1):163-74. PubMed ID: 24415869
[TBL] [Abstract][Full Text] [Related]
26. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
27. Sphingolipid Analysis Indicate Lactosylceramide as a Potential Biomarker of Inflammatory Bowel Disease in Children.
Filimoniuk A; Blachnio-Zabielska A; Imierska M; Lebensztejn DM; Daniluk U
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708181
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.
Oruç N; Ozütemiz O; Osmanoğlu N; Ilter T
Turk J Gastroenterol; 2009 Mar; 20(1):9-12. PubMed ID: 19330729
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Reese GE; Constantinides VA; Simillis C; Darzi AW; Orchard TR; Fazio VW; Tekkis PP
Am J Gastroenterol; 2006 Oct; 101(10):2410-22. PubMed ID: 16952282
[TBL] [Abstract][Full Text] [Related]
30. Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.
Tonkic A; Kumric M; Akrapovic Olic I; Rusic D; Zivkovic PM; Supe Domic D; Sundov Z; Males I; Bozic J
World J Gastroenterol; 2024 Apr; 30(13):1899-1910. PubMed ID: 38659482
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of serum miR-486 and miR-25 in ulcerative colitis and Crohn's disease: Correlations with disease activity, extent, and location.
Abdelazim SA; Shaker OG; Ali O; El-Tawil M; Senousy MA
Pathol Res Pract; 2023 Dec; 252():154910. PubMed ID: 37939427
[TBL] [Abstract][Full Text] [Related]
32. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.
Herrlinger KR; Dittmann R; Weitz G; Wehkamp J; Ludwig D; Schwab M; Stange EF; Fellermann K
Inflamm Bowel Dis; 2004 May; 10(3):229-33. PubMed ID: 15290916
[TBL] [Abstract][Full Text] [Related]
33. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
Paul S; Boschetti G; Rinaudo-Gaujous M; Moreau A; Del Tedesco E; Bonneau J; Presles E; Mounsef F; Clavel L; Genin C; Flourié B; Phelip JM; Nancey S; Roblin X
J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876
[TBL] [Abstract][Full Text] [Related]
34. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
[TBL] [Abstract][Full Text] [Related]
35. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases.
Ananthakrishnan AN; Cheng SC; Cai T; Cagan A; Gainer VS; Szolovits P; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1342-8.e1. PubMed ID: 24407106
[TBL] [Abstract][Full Text] [Related]
36. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984
[TBL] [Abstract][Full Text] [Related]
37. Decreased serum fetuin-A levels and active inflammatory bowel disease.
Ma P; Feng YC
Am J Med Sci; 2014 Jul; 348(1):47-51. PubMed ID: 24487480
[TBL] [Abstract][Full Text] [Related]
38. Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.
Saadah OI; Al-Harthi SE; Al-Mughales JA; Bin-Taleb YY; Baeshen RS
Int J Clin Exp Pathol; 2015; 8(12):16000-6. PubMed ID: 26884875
[TBL] [Abstract][Full Text] [Related]
39. Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease.
Linares PM; Algaba A; Urzainqui A; Guijarro-Rojas M; González-Tajuelo R; Garrido J; Chaparro M; Gisbert JP; Bermejo F; Guerra I; Castellano V; Fernández-Contreras ME
Dig Dis Sci; 2017 Oct; 62(10):2744-2754. PubMed ID: 28823012
[TBL] [Abstract][Full Text] [Related]
40. Soluble ST2: a new and promising activity marker in ulcerative colitis.
Díaz-Jiménez D; Núñez LE; Beltrán CJ; Candia E; Suazo C; Alvarez-Lobos M; González MJ; Hermoso MA; Quera R
World J Gastroenterol; 2011 May; 17(17):2181-90. PubMed ID: 21633527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
